

Substitute for form 1449A/PTO

PTO/SB08A (08-03)

U.S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**SHEET 1 of 1**

**COMPLETE IF KNOWN**

Application Number	10/699277
Confirmation Number	
Filing Date	October 31, 2003
First Named Inventor	Hird et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	8473MR2

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS


FOREIGN PATENT DOCUMENT							
EXAMINER INITIALS*	Cite No. <sup>†</sup>	Country Code <sup>§</sup> Number <sup>¶</sup>	Kind Code <sup>®</sup> (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	†*
KWJ		WO 00/40569 A1		07-13-2000	Alizyme Therapeutics Ltd.		
EXAMINER	/Kevin Weddington/ (04/27/2007)				DATE CONSIDERED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

8473MR2 PTO-SB08  
(Revised for P&G use 10/8/2003)


 Please type a plus sign (+) inside this box → (+)  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

# BEST AVAILABLE COPY

SUPPLEMENTAL PTO/SB08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031  
 Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 1

### COMPLETE IF KNOWN

Application Number	10/083,218
Confirmation Number	8600
Filing Date	February 26, 2002
First Named Inventor	Bryn (NMN) Hird
Group Art Unit	
Examiner Name	
Attorney Docket Number	847,3H

## U. S. PATENT DOCUMENTS

EXAMINER INITIALS <sup>1</sup>	Cite No. <sup>2</sup>	DOCUMENT NUMBER Number - Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/KW/	1	US-6,650,222	07/22/1997	DesMarais et al.	
/KW/	2	US-6,048,908	04/11/2000	Kitagawa	

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS <sup>1</sup>	Cite No. <sup>2</sup>	FOREIGN PATENT DOCUMENT Country Code <sup>3</sup> Number <sup>3</sup> Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	<sup>4</sup>
/KW/	3	DE 199 42 385 A1	06/09/1999	Belsel		
/KW/	4	EP 0901792 A1	03/17/1999	Suwelack		
/KW/	5	EP 1214934 A2	09/06/2002	Ratjen		
/KW/	6	WO 01/17377 A1	03/15/2001	Belsel		
/KW/	7	WO 98/51408 A1	11/19/1998	Chen		

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER	MARKOVA EA: Treatment of Alimentary Obesity with Oxygen Foam <sup>5</sup> Vrachebnoe Delo, vol. 6, 1971, pages 106-108, XP001120225 Issn: 0049-6804 Abstract	DATE CONSIDERED
/Kevin Weddington/ (04/27/2007)		

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP, 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the sheet under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → (+)

JAN 26 2004

PTO/SB08A 10-01/

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 2

## COMPLETE IF KNOWN

Application Number	10/083,218
Confirmation Number	8600
Filing Date	February 26, 2002
First Named Inventor	Bryn (NMN) Hird
Group Art Unit	
Examiner Name	
Attorney Docket Number	8374M


## U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.	DOCUMENT NUMBER Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/KW/	1	US-3,600,186	08/17/1971	Mattson et al.	
/KW/	2	US-3,688,763	09/05/1972	Cromarty	
/KW/	3	US-3,923,972	12/02/1975	Fields et al.	
/KW/	4	US-3,923,976	12/02/1975	Regife Vega et al.	
/KW/	5	US-3,980,968	09/14/1976	Ma	
/KW/	6	US-3,980,770	09/14/1976	Ingelman et al.	
/KW/	7	US-4,005,195	01/25/1977	Jandacek	
/KW/	8	US-4,039,489	08/02/1977	Fletcher et al.	
/KW/	9	US-4,211,765	08/08/1980	Johnson et al.	
/KW/	10	US-4,223,023	09/16/1980	Furda	
/KW/	11	US-4,340,699	07/20/1982	Grouiller	
/KW/	12	US-4,401,682	08/30/1983	Battista	
/KW/	13	US-4,432,968	02/21/1984	Page et al.	
/KW/	14	US-4,598,089	07/01/1986	Hadvary et al.	
/KW/	15	US-5,331,015	07/19/1994	DesMarais et al.	
/KW/	16	US-5,447,953	09/05/1995	Isler et al.	
/KW/	17	US-5,451,416	09/19/1995	Johnston et al.	
/KW/	18	US-5,453,282	09/26/1995	Kanauchi et al.	
/KW/	19	US-5,534,284	07/09/1996	Corrigan et al.	
/KW/	20	US-5,603,950	02/18/1997	Ratjen et al.	
/KW/	21	US-6,030,953	02/29/2000	Bailey et al.	
/KW/	22	US-6,077,556	06/20/2000	Letton et al.	
/KW/	23	US-6,251,421 B1	06/26/2001	Niazi	

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.	FOREIGN PATENT DOCUMENT Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T*
/KW/	24	WO 99/34787 A2	07/15/1999	Mandeville et al.		
/KW/	25	WO 00/09122 A1	02/24/2000	Hoffmann et al.		
/KW/	26	WO 00/09123 A1	02/24/2000	Hoffmann et al.		
/KW/	27	WO 00/40247 A1	07/13/2000	Alizm Therapeutics Ltd.		
/KW/	28	WO 00/40569 A1	07/13/2000	Alizm Therapeutics Ltd.		
/KW/	29	WO 99/47183 A1	09/23/1999	Procter & Gamble Co.		
/KW/	30	WO 01/53278 A1	07/26/2001	Alizm Therapeutics Ltd.		
/KW/	31	EP 047217 B1	09/03/1997	Ratjen		

/Kevin Weddington/ (04/27/2007)



PTO/SB08A-10-01

Approved for use through 10/31/2002 OMB 0651-0031  
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449-A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

SHEET 2 of 2

**COMPLETE IF KNOWN**

Application Number	10/083,218
Confirmation Number	8600
Filing Date	February 26, 2002
First Named Inventor	Bryn (NMN) Hird
Group Art Unit	
Examiner Name	
Attorney Docket Number	8374M

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Country Code <sup>2</sup>	Number <sup>3</sup>	Kind Code <sup>4</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
/KW/	32	JP	56161319*		12/11/1981	Shin-Etsu Chemical Indust. Co. Ltd.		
/KW/	33	JP	2001048086*		02/20/2001	Kyodo Kumiai Tsukuba Hitech Kenkyukai		

\* English Abstract with Japanese Patent

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>5</sup>
/KW/	34	COMAI et al., "Antiobesity Activity of Pluronic L-101", <u>International J. of Obesity</u> , 1980, pp. 33-42, Vol. 4.	
/KW/	35	VOLPENHEIN et al., "Effect of Non-absorbable Lipid, Sucrose Polyester on the Absorption", <u>J. of Toxicology &amp; Environmental Health</u> , 1980, pp. 679-683, Vol. 6.	
/KW/	37	MUTTER et al., "Reduction in the Body Content of DDE in the Mongolian Gerbil Treated With Sucrose Polyester and Caloric Restriction", <u>Toxicology &amp; Applied Pharmacology</u> , 1988, pp. 428-435, Vol. 92.	
/KW/	38	CAVALIER et al., "Inhibition of Human Gastric and Pancreatic Lipases by Chiral Alkylphosphonates. A Kinetic Study With 1,2-didecanoyl-sn-glycerol Monolayer", <u>Chemistry and Physics of Lipids</u> , 1999, pp. 3-31, Vol. 100.	
/KW/	39	GEUSAU et al., "Olestra Increases Faecal Excretion of 2,3,7,8-tetrachlorodibenzo-p-dioxin", <u>The Lancet</u> , 1999, pp. 1266-1267, Vol. 354.	
/KW/	40	MOSEF et al., "A Non-Absorbable Dietary Fat Substitute Enhances Elimination of Persistent Lipophilic Contamination in Humans", <u>Chemosphere</u> , 1999, pp. 1513-1521, Vol. 39 No. 9.	
/KW/	41	LENGSFELD et al., "Effect of Orlistat and Chitosan on Faecal Fat Excretion in Young Healthy Volunteers", <u>Obesity Research</u> , November 1999, pp. 50S, Vol. 7, Suppl. 1.	
/KW/	42	YAMAMOTO et al., "Anti-obesity Effects of Lipase Inhibitor CT-II, an Extract from Edible Herbs, Nomame Herba, on Rats Fed a High-fat diet", <u>International J. of Obesity</u> , 2000, pp. 758-764, Vol. 24.	
/KW/	43	CHIOU et al., "Synthetic Routes and Lipase-Inhibiting Activity of Long-Chain $\alpha$ -Keto Amides", <u>Lipids</u> , 2001, pp. 535-542, Vol. 36, No. 5.	
/KW/	44	HAN et al., "Anti-obesity Effects in Rodents of Dietary Teasaponin, a Lipase Inhibitor", <u>International J. of Obesity</u> , 2001, pp. 1459-1464, Vol. 25.	
EXAMINER	/Kevin Weddington/ (04/27/2007)		DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → (+)

PTO/SB08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031  
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 2

## COMPLETE IF KNOWN

Application Number	10/251376
Confirmation Number	
Filing Date	9/20/02
First Named Inventor	Bryn (NMN) Hird & Ronald James Jandacek
Group Art Unit	
Examiner Name	
Attorney Docket Number	8473MRL

## U. S. PATENT DOCUMENTS

EXAMINER INITIALS <sup>1</sup>	Cite No. <sup>2</sup>	DOCUMENT NUMBER Number - Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/KW/	1	US-3,600,188	08/17/1971	Mattson et al.	
/KW/	2	US-3,688,763	09/05/1972	Cromarty	
/KW/	3	US-3,923,972	12/02/1975	Fields et al.	
/KW/	4	US-3,923,978	12/02/1975	Regife Vega et al.	
/KW/	5	US-3,980,968	09/14/1978	Ma	
/KW/	6	US-3,980,770	09/14/1978	Ingelman et al.	
/KW/	7	US-4,005,195	01/25/1977	Jandacek	
/KW/	8	US-4,039,489	08/02/1977	Fletcher et al.	
/KW/	9	US-4,211,765	08/08/1980	Johnson et al.	
/KW/	10	US-4,223,023	09/16/1980	Furda	
/KW/	11	US-4,340,699	07/20/1982	Groullier	
/KW/	12	US-4,401,682	08/30/1983	Battista	
/KW/	13	US-4,432,968	02/21/1984	Page et al.	
/KW/	14	US-4,598,089	07/01/1986	Hadvary et al.	
/KW/	15	US-5,331,018	07/19/1994	DesMarais et al.	
/KW/	16	US-5,447,953	09/05/1995	Isler et al.	
/KW/	17	US-5,451,416	08/19/1995	Johnston et al.	
/KW/	18	US-5,453,282	09/26/1995	Kanauchi et al.	
/KW/	19	US-5,534,284	07/09/1998	Corrigan et al.	
/KW/	20	US-5,603,950	02/18/1997	Ratjen et al.	
/KW/	21	US-6,030,953	02/29/2000	Bailey et al.	
/KW/	22	US-6,077,558	06/20/2000	Letton et al.	
/KW/	23	US-6,251,421 B1	06/26/2001	Niaz	

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS <sup>1</sup>	Cite No. <sup>2</sup>	FOREIGN PATENT DOCUMENT Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
/KW/	24	WO 99/34787 A2	07/15/1999	Mandeville et al.		
/KW/	25	WO 00/09122 A1	02/24/2000	Hoffmann et al.		
/KW/	26	WO 00/09123 A1	02/24/2000	Hoffmann et al.		
/KW/	27	WO 00/40247 A1	07/13/2000	Alizme Therapeutics Ltd.		
/KW/	28	WO 00/40569 A1	07/13/2000	Alizme Therapeutics Ltd.		
/KW/	29	WO 99/47183 A1	09/23/1999	Procter & Gamble Co.		
/KW/	30	WO 01/53278 A1	07/26/2001	Alizme Therapeutics Ltd.		
/KW/	31	EP 047217 B1	09/03/1997	Ratjen		

/Kevin Weddington/ (04/27/2007)

# BEST AVAILABLE COPY

case type plus sign (+) inside this box → [++]

PTO/SB08A (10-01)

JAN 26 2004

Approved for use through 10/31/2002 OMB 0651-0031  
Patent and Trademark Office, U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

### COMPLETE IF KNOWN

Application Number	10/251376
Confirmation Number	
Filing Date	9/20/02
First Named Inventor	Bryn (NMN) Hird & Ronald James Jandacek
Group Art Unit	
Examiner Name	
Attorney Docket Number	8473MRL

HEET 2 of 2

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.	Country Code <sup>2</sup>	Number <sup>2</sup>	Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Chd Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
/KW/	32	JP	56161318 <sup>2</sup>		12/11/1981	Shin-Etsu Chemical Indust. Co. Ltd.		
/KW/	33	JP	2001048088 <sup>2</sup>		02/20/2001	Kyodo Kumiai Tsukuba Hitech Kenkyukai		

\* English Abstract with Japanese Patent

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>4</sup>
/KW/	34	COMAI et al., "Antibesity Activity of Pluronic L-101", <u>International J. of Obesity</u> , 1980, pp. 33-42, Vol. 4.	
/KW/	35	VOLPENHEIN et al., "Effect of Non-absorbable Lipid, Sucrose Polyester on the Absorption", <u>J. of Toxicology &amp; Environmental Health</u> , 1980, pp. 679-683, Vol. 6.	
/KW/	37	MUTTER et al., "Reduction in the Body Content of DDE in the Mongolian Gerbil Treated With Sucrose Polyester and Caloric Restriction", <u>Toxicology &amp; Applied Pharmacology</u> , 1988, pp. 428-435, Vol. 92.	
/KW/	38	CAVALIER et al., "Inhibition of Human Gastric and Pancreatic Lipases by Chiral Alkylphosphonates. A Kinetic Study With 1,2-didecanoyl-sn-glycerol Monolayer", <u>Chemistry and Physics of Lipids</u> , 1999, pp. 3-31, Vol. 100.	
/KW/	39	GEUSAU et al., "Olestra Increases Faecal Excretion of 2,3,7,8-tetrachlorodibenzo-p-dioxin", <u>The Lancet</u> , 1999, pp. 1266-1267, Vol. 354.	
/KW/	40	MOSER et al., "A Non-Absorbable Dietary Fat Substitute Enhances Elimination of Persistent Lipophilic Contamination in Humans", <u>Chemosphere</u> , 1999, pp. 1513-1521, Vol. 39 No. 9.	
/KW/	41	LENGSFELD et al., "Effect of Orlistat and Chitosan on Faecal Fat Excretion in Young Healthy Volunteers", <u>Obesity Research</u> , November 1999, pp. 50S, Vol. 7, Suppl. 1.	
/KW/	42	YAMAMOTO et al., "Anti-obesity Effects of Lipase Inhibitor CT-II, an Extract from Edible Herbs, Nomame Herba, on Rats Fed a High-fat diet", <u>International J. of Obesity</u> , 2000, pp. 758-764, Vol. 24.	
/KW/	43	CHIOU et al., "Synthetic Routes and Lipase-Inhibiting Activity of Long-Chain $\alpha$ -Keto Amides", <u>Lipids</u> , 2001, pp. 535-542, Vol. 36, No. 5.	
/KW/	44	HAN et al., "Anti-obesity Effects in Rodents of Dietary Teasaponin, a Lipase Inhibitor", <u>International J. of Obesity</u> , 2001, pp. 1459-1464, Vol. 25.	

EXAMINER /Kevin Weddington/ (04/27/2007)

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). \*See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

Burd n Hour Stat ment: This form is estimated to tak 2.0 hours t complete. Time will vary d pending upon the needs of the individual case. Any comments n the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.